化工儀器網(wǎng)>產(chǎn)品展廳>生命科學(xué)儀器>神經(jīng)生物學(xué)儀器>細(xì)胞/組織支持系統(tǒng)> Sf9昆蟲(chóng)卵巢細(xì)胞(附鑒定報(bào)告
Sf9昆蟲(chóng)卵巢細(xì)胞(附鑒定報(bào)告
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱(chēng) 上海富雨生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/2/12 10:55:20
- 訪問(wèn)次數(shù) 136
聯(lián)系方式:陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息,謝謝!
昆蟲(chóng)卵巢細(xì)胞Sf9
種屬 | 草地貪夜蛾 |
別稱(chēng) | SF9; sf9; SF-9; Sf-9; sf-9; Sf 9; Spodoptera frugiperda clone 9; Sf clone 9; IPLB-Sf-9AE; IPLB-SF-9AE; IPLB-SF-9; IPLB-Sf-9; IPLB-Sf9 |
組織來(lái)源 | 卵巢 |
傳代比例/細(xì)胞消化 | 1:2傳代 ,懸浮部分離心收集(1000RPM,5分鐘) ,貼壁部分消化1-3分鐘 |
培養(yǎng)基配置 | TNM-FH昆蟲(chóng)培養(yǎng)基;10%胎牛血清;1%雙抗 |
簡(jiǎn)介 | Sf9細(xì)胞是源于雌性草地貪夜蛾蛹的卵巢組織 ,可以用于復(fù)制桿狀病毒表達(dá)載體。 |
形態(tài) | 上皮細(xì)胞樣 |
生長(zhǎng)特征 | 貼壁 ,懸浮混合生長(zhǎng) |
倍增時(shí)間 | ~50h |
保藏機(jī)構(gòu) | ATCC; CRL-1711 |
備注 | 該細(xì)胞為半懸浮和半貼壁細(xì)胞 ,懸浮細(xì)胞離心收集 ,貼壁細(xì)胞消化處理 ,該細(xì)胞為28℃培養(yǎng) ,不需要二氧化碳。 |
Remarkable developments in immuno-oncology have changed the landscape of gastric cancer (GC) treatment. Because immunotherapy intervenes with tumor immune response rather than directly targeting tumor cells, it is important to develop a greater understanding of tumor immunity. This review paper summarizes the tumor
immune reaction and immune escape mechanisms while focusing on the role of T cells and their co-inhibitory signals, such as the immune checkpoint molecules programmed death-1 and programmed deathligand 1 (PD-L1).validate this in sitro assay.Tumor infiltrating leukocytes (TILs) are an integral component of the tumor microenvironment and have been found to correlate with prognosis and response to therapy.
immune reaction and immune escape mechanisms while focusing on the role of T cells and their co-inhibitory signals, such as the immune checkpoint molecules programmed death-1 and programmed deathligand 1 (PD-L1).validate this in sitro assay.Tumor infiltrating leukocytes (TILs) are an integral component of the tumor microenvironment and have been found to correlate with prognosis and response to therapy.